

Learner Notification

City of Hope

2025/2026 COH - CCGCoP Review Course

Date of CE Release: 06-01-2025

Date of CE Expiration: 06-01-2026

Location: Online

Acknowledgement of Financial Commercial Support

No financial commercial support was received for this educational activity.

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles. You must participate in the entire activity as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Joint Accreditation Statement



In support of improving patient care, this activity has been planned and implemented by Amedco LLC and City of Hope. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Amedco Joint Accreditation Provider Number: 4008163

Professions in scope for this activity are listed below.

Physicians

Amedco LLC designates this material for a maximum of 34.0 *AMA PRA Category 1 Credits™* for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Objectives - After Attending This Program You Should Be Able To

1. Define the basic principles of gene structure, function, and regulation.
2. Describe fundamentals of the genetic cancer risk assessment (GCRA) process.
3. Explain the methods and limitations of genetic analysis for hereditary breast and ovarian cancer.
4. Recognize and apply mutation probability and empiric risk assessment models for breast cancer.
5. Recognize features associated with hereditary risk for colorectal and other gastrointestinal cancers.
6. Recognize clinical features of hereditary endocrine neoplasia syndromes.
7. Recognize clinical features of hereditary cancer syndromes with pediatric manifestations.
8. Identify genetic counseling and testing issues associated with pediatric hereditary cancer syndromes.
9. Define disease characteristics of hereditary syndromes classified as genodermatoses.
10. Compare Describe the differences between a high, moderate, and low penetrance cancer susceptibility gene.
11. Recognize ethical, legal and social issues relevant to cancer genetics counseling and testing.
12. Recognize key psychological principles and how they generalize across hereditary cancer syndromes.

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

Name	Commercial Interest:Relationship
Mary Jane Berry	NA
Kathleen Blazer	Astra Zeneca:Research Grant Overall Principal Investigator
Kelly Bolton	Servier:Research Grant Overall Principal Investigator Servier:Scientific/Medical Advisory Board Member
ALEXANDRA CAPASSO	NA
Anuja Chitre	NA
Jane Churpek	UpToDate, Inc:Other
Julie Culver	NA
Sandra Dreike	NA
Hunaydah Elfarawi	NA
Tobias Else	Merck:Scientific/Medical Advisory Board Member
Lauren Gima	NA
Veda Giri	NA
Heather Hampel	GI OnDemand:Consultant GI OnDemand:Other Genome Medical:Private Stock Shareholder Exact Sciences, LS CancerDiag OY:Scientific/Medical Advisory Board Member
Karen Hurley	NA
Gregory Idos	NA
Joanne Jeter	NA
Junne Kamihara	PanTher Therapeutics, ROME Therapeutics, TellBio, Inc.:Private Stock Shareholder Sonata Therapeutics, abrdn, Moderna, Ikena Oncology:Consultant ImproveBio, Inc.:Scientific/Medical Advisory Board Member Sanofi, ACD-Biotechnie, AVA LifeScience GmbH, Incyte Pharmaceuticals:Research Grant Overall Principal Investigator
Elisabeth King	NA
Sonia Kupfer	Myriad, Invitae, PRECEDE:Other
Allison Kurian	Ambry Genetics, Myriad Genetics:Other
Phyllis Leung	NA
Katherine Lord	NA
John Luna	NA
Lisa Madlensky	VieCure:Scientific/Medical Advisory Board Member
Rachelle Manookian	NA
Bitu Nehoray	NA
Gloria Nunez	NA
Wai Park	NA
Colin Pritchard	NA
Padma Rajagopal	NA
Kathryn Reyes	NA
Christina Rybak	Natera:Public Stock Shareholder
Tracy Sandstrom	NA
Susan Shehayeb	NA

Brian Shuch	NA
Elise Sobotka	NA
Ilana Solomon	NA
Dev Tanna	NA
Michelle Weaver Knowles	Myriad Genetics, Ambry Genetics, Merck :Speakers Bureau
Kaila Wilson	NA
Elyssa Zukin	NA
